Design and pharmacokinetical aspects for the use of inorganic nanoparticles in radiomedicine

British Journal of Radiology

Volumn 89, Issue 1057, 2016, Pages

  Puntes, Victor ^a,b,c  

^a INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^b CATALAN INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY ICN2   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

NANOPARTICLE; ANTINEOPLASTIC AGENT;

ADSORPTION; CHEMORADIOTHERAPY; CORROSION; DISSOLUTION; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIATION DOSE; RADIODIAGNOSIS; RADIOLOGY; RADIOTHERAPY; REVIEW; SEDIMENTATION; SYNTHESIS; TOXIC DOSE; HUMAN; NEOPLASMS; TISSUE DISTRIBUTION;

ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; HUMANS; NANOPARTICLES; NEOPLASMS; TISSUE DISTRIBUTION;

EID: 84951049935     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr.20150210     Document Type: Review

References (72)

1. Alivisatos P, Barbara PF, Welford Castleman A, Chang J, Dixon DA, Klein ML, et al. From molecules to materials: current trends and future directions. Adv Mater 1998; 10: 1297-336. doi: 10.1002/(SICI)1521-4095 (199811)10:16, 1297:AID-ADMA1297.3.0. CO;2-7
2. Alivisatos P. Less is more in medicine. Sci Am 2001; 285: 66-73. doi: 10.1038/scientifica-merican0901-66
3. Mi Y, Guo Y, Feng SS. Nanomedicine for multimodality treatment of cancer. Nano-medicine 2012; 7: 1791-4. doi: 10.2217/nnm.12.159
4. Westermann AM, Jones EL, Schem BC, van der Steen-Banasik EM, Koper P, Mella O, et al. Results of triple-modality treatment combining radiotherapy, chemotherapy, and hyperthermia. Cancer 2005; 104: 763-70. doi: 10.1002/cncr.21128
5. Westermann A, Mella O, Van Der Zee J, Jones EL, Van Der Steen-Banasik E, Koper P, et al. Long-term survival data of triple modality treatment of stage IIB-III-IVA cervical cancer with the combination of radiotherapy, chemotherapy and hyperthermia-an update. Int J Hyperthermia 2012; 28: 549-53. doi: 10.3109/02656736.2012.673047
6. Khlebtsov N, Dykman L. Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies. Chem Soc Rev 2011; 40: 1647-71. doi: 10.1039/c0cs00018c
7. Hainfeld JF, Dilmanian FA, Slatkin DN, Smilowitz HM. Radiotherapy enhancement with gold nanoparticles. J Pharm Pharmacol 2008; 60: 977-85. doi: 10.1211/jpp.60.8.0005
8. Atkins HL, Fairchild RG, Robertson JS, Greenberg D. Effect of absorption edge filters on diagnostic X-ray spectra. Radiology 1975; 115: 431-7. doi: 10.1148/115.2.431
9. Luchette M, Korideck H, Makrigiorgos M, Tillement O, Berbeco R. Radiation dose enhancement of gadolinium-based AGuIX nanoparticles on HeLa cells. Nanomedicine 2014; 10: 1751-5. doi: 10.1016/j. nano.2014.06.004
10. Soo Choi H, Liu W, Misra P, Tanaka E, Zimmer JP, Itty Ipe B, et al. Renal clearance of quantum dots. Nat Biotechnol 2007; 25: 1165-70. doi: 10.1038/nbt1340
11. Casals E, Vazquez-Campos S, Bastus N, Puntes V. Distribution and potential tox-icity of engineered inorganic nanoparticles and carbon nanostructures in biological systems. Trends Anal Chem 2008; 27: 672-83.
12. Comenge J, Sotelo C, Romero F, Gallego O, Barnadas A, Parada TG, et al. Detoxifying antitumoral drugs via nanoconjugation: the case of gold nanoparticles and cisplatin. PLoS ONE 2012; 7: e47562. doi: 10.1371/journal. pone.0047562
13. Kao CY, Hoffman EA, Beck KC, Bellamkonda RV, Annapragada AV. Long-residence-time nano-scale liposomal iohexol for X-ray-based blood pool imaging. Acad Radiol 2003; 10: 475-83.
14. Schmiedl UP, Krause W, Leike J, Sachse A. CT blood pool enhancement in primates with-lopromide-carrying liposomes containing soy phosphatidyl glycerol. Acad Radiol 1999; 6: 164-9. doi: 10.1016/S1076-6332(99)80402-4
15. Torchilin VP. PEG-based micelles as carriers of contrast agents for different imaging modalities. Adv Drug Deliv Rev 2002; 54: 235-52. doi: 10.1016/S0169-409X(02) 00019-4
16. Vera DR, Mattrey RF. A molecular CT blood pool contrast agent. Acad Radiol 2002; 9: 784-92. doi: 10.1016/S1076-6332(03) 80348-3
17. Fruman SA, Harned RK 2nd, Marcus D, Kaufman S, Swenson RB, Bernardino ME. Perfluoroctyl bromide as a blood pool contrast agent for computed tomographic angiography. Acad Radiol 1994; 1: 151-3. doi: 10.1016/S1076-6332(05)80834-7
18. Torchilin VP, Frank-Kamenetsky MD, Wolf GL. CT visualization of blood pool in rats by using long-circulating, iodine-containing micelles. Acad Radiol 1999; 6: 61-5. doi: 10.1016/S1076-6332(99)80063-4
19. Ruenraroengsak P, Cook JM, Florence AT. Nanosystem drug targeting: facing up to complex realities. J Control Release 2010; 141: 265-76.
20. Lu W, Xiong C, Zhang G, Huang Q, Zhang R, Zhang JC, et al. Targeted photothermal ablation of murine melanomas with melanocyte-stimulating hormone analog-conjugated hollow gold nanospheres. Clin Cancer Res 2009; 15: 876-86. doi: 10.1158/1078-0432.CCR-08-1480
21. Gleich B, Weizenecker J. Tomographic imaging using the nonlinear response of magnetic particles. Nature 2005; 435: 1214-17. doi: 10.1038/nature03808
22. Butterworth KT, McMahon SJ, Currell FJ, Prise KM. Physical basis and biological mechanisms of gold nanoparticle radiosen-sitization. Nanoscale 2012; 4: 4830-8. doi: 10.1039/c2nr31227a
23. Carter JD, Cheng NN, Qu Y, Suarez GD, Guo T. Nanoscale energy deposition by X-ray absorbing nanostructures. J Phys Chem B 2007; 111: 11622-5. doi: 10.1021/jp075253u
24. McMahon SJ, Hyland WB, Brun E, Butterworth KT, Coulter JA, Douki T, et al. Energy dependence of gold nanoparticle radio-sensitization in plasmid DNA. J Phys Chem C 2011; 115: 20160-7. doi: 10.1021/jp206854s
25. Somorjai, GA, Contreras AM, Montano M, Rioux RM. Clusters, surfaces, and catalysis. Proc Natl Acad Sci USA 2006; 103: 10577-83. doi: 10.1073/pnas.0507691103
26. Douple EB, Richmond RC. Radiosensitiza-tion of hypoxic tumor cells by cis-and trans-dichlorodiammineplatinum (II). Int J Radiat Oncol Biol Phys 1979; 5: 1369-72.
27. Zhang N, Erjala K, Kulmala J, Qiu X, Sundvall M, Elenius K, et al. Concurrent cetuximab, cisplatin, and radiation for squa-mous cell carcinoma of the head and neck in vitro. Radiother Oncol 2009; 92: 388-92. doi: 10.1016/j.radonc.2009.04.019
28. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000; 65: 271-84. doi: 10.1016/S0168-3659(99) 00248-5
29. Bulte JW, Kraitchman DL. Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed 2004; 17: 484-99. doi: 10.1002/nbm.924
30. Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater 2013; 12: 991-1003. doi: 10.1038/nmat3776
31. X-Ray Mass Attenuation Coefficients. [Cited 20 October 2015.] Available from: http://physics.nist.gov/PhysRefData/XrayMassCoef
32. Hainfeld JF, Slatkin DN, Smilowitz HM. The use of gold nanoparticles to enhance radiotherapy in mice. Phys Med Biol 2004; 49: N309-15. doi: 10.1088/0031-9155/49/18/N03
33. Bastus NG, Comenge J, Puntes V. Kinetically controlled seeded growth synthesis of citrate-stabilized gold nanoparticles of up to 200 nm: size focusing versus Ostwald ripening. Langmuir 2011; 27: 11098-105.
34. Eugenii K, Itamar W. Integrated nanoparticle-biomolecule hybrid systems: synthesis, properties, and applications. Angew Chem Int Ed Engl 2004; 43: 6042-108.
35. Bastus NG, Casals E, Vázquez-Campos S, Puntes V. Reactivity of engineered inorganic nanoparticles and carbon nanostructures in biological media. Nanotoxicology 2008; 2: 99-112.
36. Casals E, Pfaller T, Duschl A, Oostingh G, Puntes V. Time evolution of the nanoparticle protein corona. ACS Nano 2010; 4: 3623-32. doi: 10.1021/nn901372t
37. Lundqvist M, Stigler J, Elia G, Lynch I, Cedervall T, Dawson KA. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci USA 2008; 105: 14265-70. doi: 10.1073/pnas.0805135105
38. Cedervall T, Lynch I, Lindman S, Bergga°rd T, Thulin E, Nilsson H, et al. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc Natl Acad Sci USA 2007; 104: 2050-5.
39. Monopoli P, Walczyk D, Campbell A, Elia G, Lynch I, Bombelli FB, et al. Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. J Am Chem Soc 2011; 133: 2525-34. doi: 10.1021/ja107583h
40. Wang D, Tejerina B, Lagzi I, Kowalczyk B, Grzybowski BA. Bridging interactions and selective nanoparticle aggregation mediated by monovalent cations. Acs Nano 2011; 5: 530-6. doi: 10.1021/nn1025252
41. Izak-Nau E, Voetz M, Eiden S, Duschl A, Puntes V. Altered characteristics of silica nanoparticles in bovine and human serum. Part Fibre Toxicol 2013; 10: 56. doi: 10.1186/1743-8977-10-56
42. Takakura Y, Hashida M. Macromolecular carrier systems for targeted drug delivery: pharmacokinetic considerations on biodis-tribution. Pharma Res 1996; 13: 820. doi: 10.1023/A:1016084508097
43. Bastús NG, Sánchez-Tilló E, Pujals S, Farrera C, López C, Giralt E, et al. Homogeneous conjugation of peptides onto gold nano-particles enhances macrophage response. ACS Nano 2009; 3: 1335-44.
44. Cho EC, Zhang Q, Xia Y, The effect of sedimentation and diffusion on cellular uptake of gold nanoparticles. Nat Nano-technol 2011; 6: 385-91. doi: 10.1038/nnano.2011.58
45. Krug HF. Nanosafety research-are we on the right track? Angew Chem Int Ed Engl 2014; 53: 12304-19.
46. Bian SW, Mudunkotuwa IA, Rupasinghe T, Grassian VH. Aggregation and dissolution of 4 nm ZnO nanoparticles in aqueous environments: influence of pH, ionic strength, size, and adsorption of humic acid. Langmuir 2011; 27: 6059-68. doi: 10.1021/la200570n
47. Israelachvili J. Intermolecular and surface forces. 2nd edn. San Diego, CA: Academic Press; 1992.
48. Rejman J, Oberle V, Zuhorn IS, Hökstra D. Size-dependent internalization of particles via the pathways of clathrin-and caveolae-mediated endocytosis. Biochem J 2004; 377: 159-69. doi: 10.1042/bj20031253
49. Lynch I, Salvati A, Kenneth A, Dawson KA. Protein-nanoparticle interactions: what does the cell see? Nat Nanotechnol 2009; 4: 546-7. doi: 10.1038/nnano.2009.248
50. Goy-López S, Juárez J, Alatorre-Meda M, Casals E, Puntes V, Taboada P, et al. Physi-cochemical characteristics of protein-NP bioconjugates: the role of particle curvature and solution conditions on human serum albumin conformation and fibrillogenesis inhibition. Langmuir 2012; 28: 9113-26. doi: 10.1021/la300402w
51. Geranio L, Heuberger M, Nowack B. The behavior of silver nanotextiles during washing. Environ Sci Technol 2009; 43: 8113-18. doi: 10.1021/es9018332
52. Elzey S, Grassian VH. Agglomeration, isolation and dissolution of commercially manufactured silver nanoparticles in aqueous environments. J Nanopart Res 2010; 12: 1945-58. doi: 10.1007/s11051-009-9783-y
53. Li X, Lenhart JJ, Walker HW. Aggregation kinetics and dissolution of coated silver nanoparticles. Langmuir 2012; 28: 1095-104. doi: 10.1021/la202328n
54. Li XA, Lenhart JJ, Walker HW. Dissolution-accompanied aggregation kinetics of silver nanoparticles. Langmuir 2010; 26: 16690-8. doi: 10.1021/la101768n
55. Liu JY, Hurt RH. Ion release kinetics and particle persistence in aqueous nano-silver colloids. Environ Sci Technol 2010; 44: 2169-75. doi: 10.1021/es9035557
56. Borm P, Klaessig FC, Landry TD, Moudgil B, Pauluhn J, Thomas K, et al. Research strategies for safety evaluation of nanomate-rials, part v: role of dissolution in biological fate and effects of nanoscale particles. Toxicol Sci 2006; 90: 23-32. doi: 10.1093/toxsci/kfj084
57. Auffan M, Rose J, Bottero J-Y, Lowry GV, Jolivet J-P, Wiesner MR. Towards a definition of inorganic nanoparticles from an environmental, health and safety perspective. Nat Nanotechnol 2009; 4: 634-41. doi: 10.1038/nnano.2009.242
58. Ojea-Jimenez I, Puntes V. Instability of cationic gold nanoparticle bioconjugates: the role of citrate ions. J Am Chem Soc 2009; 131: 13320-7.
59. Casals E, Barrena R, Garćia A, González E, Delgado L, Busquets-Fité M, et al. Programmed iron oxide nanoparticles disintegration in anaerobic digesters boosts biogas production. Small 2014; 10: 2801-8. doi: 10.1002/smll.201303703
60. Maggiorella L, Barouch G, Devaux C, Pottier A, Deutsch E, Bourhis J, et al. Nanoscale radiotherapy with hafnium oxide nanopar-ticles. Future Oncol 2012; 8: 1167-81. doi: 10.2217/fon.12.96
61. Berbeco R, Ngwa W, Makrigiorgos M. Localized dose enhancement to tumor blood vessel endothelial cells via megavoltage X-rays and targeted gold nanoparticles: new potential for external beam radiotherapy. Int J Radiat Oncol Biol Phys 2011; 81: 270-6. doi: 10.1016/j.ijrobp.2010.10.022
62. Zhang X-D, Wu D, Shen X, Chen J, Sun Y-M, Liu P-X, et al. Size dependent radiosensiti-zation of PEG-coated gold nanoparticles for cancer radiation therapy. Biomaterials 2012; 33: 6408-19.
63. Jain S, Coulter JA, Hounsell AR, Butterworth KT, McMahon SJ, Hyland WB, et al. Cell-specific radiosensitization by gold nanopar-ticles at megavoltage radiation energies. Int J Radiat Oncol Biol Phys 2011; 79: 531-9. doi: 10.1016/j.ijrobp.2010.08.044
64. Craig GE, Brown SD, Lamprou DA, Graham D, Wheate NJ. Cisplatin-tethered gold nanoparticles that exhibit enhanced repro-ducibility, drug loading, and stability: a step closer to pharmaceutical approval? Inorg Chem 2012; 51: 3490-7. doi: 10.1021/ic202197g
65. Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007; 99: 1441-54. doi: 10.1093/jnci/djm135
66. Kumar R, Roy I, Ohulchanskky TY, Vathy LA, Bergey EJ, Sajjad M, et al. In vivo biodis-tribution and clearance studies using multi-modal organically modified silica nanoparticles. ACS Nano 2010; 4: 699-708. doi: 10.1021/nn901146y
67. Perrault SD, Walkey C, Jennings T, Fischer HC, Chan WC. Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett 2009; 9: 1909-15. doi: 10.1021/nl900031y
68. Dreher MR, Chilkoti A. Toward a systems engineering approach to cancer drug delivery. J Natl Cancer Inst 2007; 99: 983-5. doi: 10.1093/jnci/djm042
69. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006; 6: 583-92. doi: 10.1038/nrc1893
70. Tannock IF, Lee CM, Tunggal JK, Cowan DSM, Merrill J. Egorin limited penetration of anticancer drugs through tumor tissue. Clin Cancer Res 2002; 8: 878-83.
71. Huang W, Tsai P, Chen Y. Functional gold nanoparticles as photothermal agents for selective-killing of pathogenic bacteria. Nanomedicine 2013; 2: 777-87. doi: 10.2217/17435889.2.6.777
72. Higuchi ML, Gutierrez PS, Bezerra HG, Palomino SA, Aiello VD, Silvestre JM, et al. Comparison between adventitial and intimal inflammation of ruptured and nonruptured atherosclerotic plaques in human coronary arteries. Arq Bras Cardiol 2002; 79: 20-4. doi: 10.1590/S0066-782X2002001000003